CGEN:NASDAQ
Compugen Ltd
$2.10
arrow_downward
-0.94%(-0.020) 1D
Nov 13, 4:00:01 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for CGEN...
Open
$2.11
High
$2.12
Low
$2.04
Mkt. cap
198.93M
Avg. vol.
229.42K
Volume
209.64K
P/E ratio
5.78
52-wk high
$3.24
52-wk low
$1.43
EPS
$0.36
Beta
2.85
Shares outstanding
94.73M
No. of employees
75
Open
$2.11
High
$2.12
Low
$2.04
Mkt. cap
198.93M
Avg. vol.
229.42K
Volume
209.64K
P/E ratio
5.78
52-wk high
$3.24
52-wk low
$1.43
EPS
$0.36
Beta
2.85
Shares outstanding
94.73M
No. of employees
75
News stories
From web sources and news partners
GuruFocus
·
1 day ago
Compugen Ltd (CGEN) Q3 2026 Earnings Call Highlights: Revenue Do
Yahoo! Finance Canada
·
1 day ago
Compugen Ltd (CGEN) Q3 2026 Earnings Call Highlights: Revenue Doubles as Gilead and AstraZeneca ...
Profile
Compugen Ltd. is a clinical-stage publicly traded predictive drug discovery and development company headquartered in Israel, with shares traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange. Compugen was established as computational drug discovery service provider in 1993. Compugen originally acted as service provider for pharma companies, supplying its software and computational services to predict different types of biological phenomena. It had arrangements with big companies such as Novartis AG, Abbot Laboratories and Pfizer Inc. Subsequently, Compugen made a decision to become a drug development company with its own internal pipeline, and in 2010, decided to a focus on oncology and immunology. OncoMed Pharmaceuticals and Five Prime Therapeutics are among Compugen's competitors. Wikipedia
About Compugen Ltd
CEOAnat Cohen-Dayag
Employees75
FoundedFeb 10, 1993
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websitecgen.com